Taxanes in the elderly patient with metastatic breast cancer.

No significant associations were reported between age and any pharmacokinetic parameters, although there was a borderline significant association between increasing age and increasing total drug exposure (area under the curve; P =0.055). nab-paclitaxel Although no prospective studies have been conducted to evaluate the clinical benefit of nab-paclitaxel in elderly patients with metastatic breast cancer, a retrospective analysis e

also in 11,409 other papers

In elderly patients (defined as aged ≥65 years; n=127), both bevacizumab-containing groups produced longer median PFS values versus the placebo group, similar to what was observed in the intention-to-treat (ITT) population; however, the differences did not reach statistical significance (for the 7.5 mg/kg bevacizumab group vs placebo, 9.0 vs 7.6 months, HR =0.76, P =0.35; for the 15 mg/kg bevacizumab group vs placebo, 10.3 vs 7.6 months, HR =0.63, P =0.07).

also in 111,027 other papers